Basal-cell carcinoma

Last updated
Basal-cell carcinoma
Other namesBasal-cell skin cancer, basalioma, rodent ulcer
Basalioma.jpg
An ulcerated basal cell carcinoma near the ear of a 75-year-old male
Specialty Dermatology, oncology
Symptoms Painless raised area of skin that may be shiny with small blood vessel running over it or ulceration [1]
Risk factors Light skin, ultraviolet light, radiation therapy, arsenic, poor immune function [2]
Diagnostic method Examination, skin biopsy [3]
Differential diagnosis Milia, seborrheic keratosis, melanoma, psoriasis [4]
TreatmentSurgical removal [2]
Prognosis Good [5]
Frequency~30% of white people at some point (US) [2]
DeathsRare [6]

Basal-cell carcinoma (BCC), also known as basal-cell cancer, basalioma [7] or rodent ulcer, [8] is the most common type of skin cancer. [2] It often appears as a painless raised area of skin, which may be shiny with small blood vessels running over it. [1] It may also present as a raised area with ulceration. [1] Basal-cell cancer grows slowly and can damage the tissue around it, but it is unlikely to spread to distant areas or result in death. [9]

Contents

Risk factors include exposure to ultraviolet light, having lighter skin, radiation therapy, long-term exposure to arsenic and poor immune-system function. [2] Exposure to UV light during childhood is particularly harmful. [5] Tanning beds have become another common source of ultraviolet radiation. [10] Diagnosis often depends on skin examination, confirmed by tissue biopsy. [2] [3]

It remains unclear whether sunscreen affects the risk of basal-cell cancer. [11] Treatment is typically by surgical removal. [2] This can be by simple excision if the cancer is small; otherwise, Mohs surgery is generally recommended. [2] Other options include electrodesiccation and curettage, cryosurgery, topical chemotherapy, photodynamic therapy, laser surgery or the use of imiquimod, a topical immune-activating medication. [12] In the rare cases in which distant spread has occurred, chemotherapy or targeted therapy may be used. [12]

Basal-cell cancer accounts for at least 32% of all cancers globally. [9] [13] Of skin cancers other than melanoma, about 80% are basal-cell cancers. [2] In the United States, about 35% of white males and 25% of white females are affected by BCC at some point in their lives. [2]

Basal-cell carcinoma is named after the basal cells that form the lowest layer of the epidermis. It is thought to develop from the folliculo–sebaceous–apocrine germinative cells called trichoblasts (of note, trichoblastic carcinoma is a term sometimes used to refer to a rare type of aggressive skin cancer that may resemble a benign trichoblastoma, and can also closely resemble basal cell carcinoma).

Signs and symptoms

Individuals with a basal-cell carcinoma typically present with a shiny, pearly skin nodule. However, superficial basal-cell cancer can present as a red patch similar to eczema. Infiltrative or morpheaform basal-cell cancers can present as a skin thickening or scar tissue – making diagnosis difficult without using tactile sensation and a skin biopsy. It is often difficult to visually distinguish basal-cell cancer from acne scar, actinic elastosis, and recent cryodestruction inflammation. [14]

Cause

The majority of basal-cell carcinomas occur on sun-exposed areas of the body. [15]

Pathophysiology

Micrograph of a basal-cell carcinoma, showing the characteristic histomorphologic features (peripheral palisading, myxoid stroma, artefactual clefting). H&E stain Basal cell carcinoma - 2 - intermed mag.jpg
Micrograph of a basal-cell carcinoma, showing the characteristic histomorphologic features (peripheral palisading, myxoid stroma, artefactual clefting). H&E stain

Basal-cell carcinoma is named after the basal cells that populate the lowest layer of the epidermis due to the histological appearance of the cancer cells under the microscope. [16] Nevertheless, not all basal-cell carcinomas actually originate within the basal layer. [16] Basal-cell carcinomas are thought to develop from the folliculo–sebaceous–apocrine germinative cells known as trichoblasts. Trichoblastic carcinoma is a term used to describe a rare and potentially aggressive malignancy that is also thought to arise from trichoblasts and may resemble a benign trichoblastoma (differential diagnosis can be challenging). [17] [18] [19] It has been suggested that lesions diagnosed as 'trichoblastic carcinoma' may actually themselves be basal-cell carcinoma. [20] [ needs update ]

Overexposure to sun leads to the formation of thymine dimers, a form of DNA damage. While DNA repair removes most UV-induced damage, not all crosslinks are excised. There is, therefore, cumulative DNA damage leading to mutations. Apart from the mutagenesis, overexposure to sunlight depresses the local immune system, possibly decreasing immune surveillance for new tumor cells.

Basal-cell carcinomas can often come in association with other lesions of the skin, such as actinic keratosis, seborrheic keratosis, and squamous cell carcinoma. [21] In a small proportion of cases, basal-cell carcinoma also develops as a result of basal-cell nevus syndrome, or Gorlin Syndrome, which is also characterized by keratocystic odontogenic tumors of the jaw, palmar or plantar (sole of the foot) pits, calcification of the falx cerebri (in the center line of the brain) and rib abnormalities. The cause of this syndrome is a mutation in the PTCH1 tumor suppressor gene located in chromosome 9q22.3, which inhibits the hedgehog signaling pathway. A mutation in the SMO gene, which is also on the hedgehog pathway, also causes basal-cell carcinoma. [22]

Diagnosis

Ulcerated basal-cell carcinoma affecting the skin of the nose in an elderly individual Basal cell carcinoma2.JPG
Ulcerated basal-cell carcinoma affecting the skin of the nose in an elderly individual

To diagnose basal-cell carcinomas, a skin biopsy is performed for histopathologic analyses. The most common method is a shave biopsy under local anesthesia. Most nodular basal-cell cancers can be diagnosed clinically; however, other variants can be very difficult to distinguish from benign lesions such as intradermal naevus, sebaceomas, fibrous papules, early acne scars, and hypertrophic scarring. [23] Exfoliative cytology methods have high sensitivity and specificity for confirming the diagnosis of basal cell carcinoma when clinical suspicion is high but unclear usefulness otherwise. [24]

Characteristics

High-magnification micrograph of basal-cell carcinoma High-magnification micrograph of basal-cell carcinoma.jpg
High-magnification micrograph of basal-cell carcinoma

Basal-cell carcinoma cells appear similar to epidermal basal cells, and are usually well differentiated. [25]

In uncertain cases, immunohistochemistry using BerEP4 can be used, having a high sensitivity and specificity in detecting only BCC cells. [26]

Main classes

Basal-cell carcinoma can broadly be divided into three groups, based on the growth patterns.

  1. Superficial basal-cell carcinoma, formerly referred to in-situ basal-cell carcinoma, is characterized by a superficial proliferation of neoplastic basal-cells. This tumor is generally responsive to topic chemotherapy, such as imiquimod, or fluorouracil, although surgical treatment is better able to ensure complete removal and confirm that there is not an underlying more aggressive subtype that was not sampled in the initial biopsy.
  2. Infiltrative basal-cell carcinoma, which also encompasses morpheaform and micronodular basal-cell cancer, is more difficult to treat with conservative methods, given its tendency to penetrate into deeper layers of the skin.
  3. Nodular basal-cell carcinoma includes most of the remaining categories of basal-cell cancer. It is not unusual to encounter heterogeneous morphologic features within the same tumor.

Nodular basal-cell carcinoma

Basal-cell carcinoma with nodular pattern Basal Cell Carcinoma, Nodular Pattern (6032028849).jpg
Basal-cell carcinoma with nodular pattern

Nodular basal-cell carcinoma (also known as "classic basal-cell carcinoma") accounts for 50% of all BCC. [27] It most commonly occurs on the sun-exposed areas of the head and neck. [28] : 748  [29] : 646  Histopathology shows aggregates of basaloid cells with well-defined borders, showing a peripheral palisading of cells and one or more typical clefts. [27] Such clefts are caused by shrinkage of mucin during tissue fixation and staining. [30] Central necrosis with eosinophilic, granular features may be also present, as well as mucin. The heavy aggregates of mucin determine a cystic structure. Calcification may be also present, especially in long-standing lesions. [27] Mitotic activity is usually not so evident, but a high mitotic rate may be present in more aggressive lesions. [27] Adenoidal BCC can be classified as a variant of NBCC, characterized by basaloid cells with a reticulated configuration extending into the dermis. [27]

Other subtypes

Other more specific subtypes of basal-cell carcinoma include: [28] [29] : 646–50 

TypeHistopathologyOther characteristicsImage
Cystic basal-cell carcinomaMorphologically characterized by dome-shaped, blue-gray cystic nodules. [29] : 647  SkinTumors-P7240520.jpg
Morpheaform basal-cell carcinoma (also known as "cicatricial basal-cell carcinoma", and "morphoeic basal-cell carcinoma")Narrow strands and nests of basaloid cells, surrounded by dense sclerotic stroma. [31] Aggressive [28] : 748  [29] : 647  Morpheaform basal-cell carcinoma.jpg
Infiltrative basal-cell carcinomaDeep infiltration. [29] : 647 Aggressive [29] : 647 
Micronodular basal-cell carcinomaSmall and closely spaced nests. SkinTumors-P6180318.JPG
Superficial basal-cell carcinoma (also known as "superficial multicentric basal-cell carcinoma")Occurs most commonly on the trunk and appears as an erythematous patch. [28] : 748  [29] : 647  SkinTumors-P6160271.JPG
Pigmented basal-cell carcinoma exhibits increased melanization. [28] : 748  [29] : 647 About 80% of all basal-cell carcinoma in Chinese are pigmented while this subtype is uncommon in white people. [ citation needed ]
Jacob's ulcerNodular, with central necrosis. [28] : 748  [29] : 647 Generally a large skin lesion with central necrosis. [28] : 748  [29] : 647 
Fibroepithelioma of PinkusAnastomosing epithelial strands in a fenestrated pattern [32] Most commonly occurs on the lower back. [28] : 748  [29] : 648  Basal cell carcinoma fibroepitheliomatous pattern - low mag.jpg
Polypoid basal-cell carcinomaExophytic nodules (polyp-like structures)Generally on head and neck. [29] : 648 
Pore-like basal-cell carcinomaResembles an enlarged pore or stellate pit. [29] : 648 
Aberrant basal-cell carcinomaAbsence of any apparent carcinogenic factor, and occurring in odd sites such as the scrotum, vulva, perineum, nipple, and axilla. [29] : 648 

Aggressiveness patterns

There are mainly three patterns of aggressiveness, based mainly the cohesion of cancer cells: [33]

Low-level aggressive patternModerately aggressive patternHighly aggressive pattern

Differential diagnoses

Main histological differential diagnoses of basal cell carcinoma: [27]
Differential diagnosisPathological FeaturesImage
Hair follicles Peripheral sections may look like nests, but do not display atypia, nuclei are smaller, and serial sections will reveal the rest of the hair follicle. Histopathology of hair follicle periphery.jpg
Squamous-cell carcinoma of the skin Squamous-cell carcinoma of the skin is generally distinguishable by for example relatively more cytoplasm, horn cyst formation and absence of palisading and cleft formations. Yet, a high prevalence means a relatively high incidence of borderline cases, such as basal-cell carcinoma with squamous cell metaplasia (H&E stain at left in image). BerEP4 staining helps in such cases, staining only basal-cell carcinoma cells (right in image). BCC with squamous cell metaplasia with HE and BerEP4 staining.jpg
Trichoblastoma Absence of cleft, rudimentary hair germs, papillary mesenchymal bodies. Micrographs of trichoblastoma.jpg
Adenoid cystic carcinoma Lack of basaloid cells disposed in peripheral palisades; adenoid-cystic lesion without connection to the epidermis; absence of artefactual clefts Micrograph of adenoid cystic carcinoma.jpg
Microcystic adnexal carcinoma Bland keratinocytes, keratin cysts, ductal differentiation. BerEp4- (in 60% of cases), [35] CEA+, EMA+
Trichoepithelioma [notes 1] Rims of collagen bundles, calcification, follicular/sebaceous/infundibular differentiation and cut artefacts. Cytokeratin (CK)20+, p75+, Pleckstrin homology-like domain family A member 1 + (PHLDA1+), common acute lymphoblastic leukemiaantigen + (CD10+) in tumor stroma, CK 6-, Ki-67- and Androgen Rceptor- (AR-) Trichoepithelioma (1338537528).jpg
Merkel cell carcinoma Cells arranged in a diffuse, trabecular and/or nested pattern, involving also the subcutis. Mouse Anti-Cytokeratin (CAM) 5.2+, CK20+, S100-, human leukocyte common antigen- ( LCA-), thyroid transcription factor 1- (TTF1-) Micrographs of a typical merkel cell carcinoma.jpg

Radicality

Comparison H&E stain (left) with BerEP4 immunohistochemistry staining (right) on a pathological section having BCC with squamous cell metaplasia. Only BCC cells are stained with BerEP4. BCC with squamous cell metaplasia with HE and BerEP4 staining.jpg
Comparison H&E stain (left) with BerEP4 immunohistochemistry staining (right) on a pathological section having BCC with squamous cell metaplasia. Only BCC cells are stained with BerEP4.

In suspected but uncertain BCC cells close to the resection margins, immunohistochemistry with BerEp4 can highlight the BCC cells.

Prevention

Basal-cell carcinoma is a common skin cancer and occurs mainly in fair-skinned patients with a family history of this cancer. Sunlight is a factor in about two-thirds of these cancers; therefore, doctors recommend sunscreens with at least SPF 30. However, a Cochrane review examining the effect of solar protection (sunscreen only) in preventing the development of basal-cell carcinoma or cutaneous squamous cell carcinoma found that there was insufficient evidence to demonstrate whether sunscreen was effective for the prevention of either of these keratinocyte-derived cancers. [36] The review did ultimately state that the certainty of these results was low, so future evidence could very well alter this conclusion. One-third occur in non-sun-exposed areas; thus, the pathogenesis is more complex than UV exposure as the cause. [15]

The use of a chemotherapeutic agent such as 5-Fluorouracil or imiquimod can prevent the development of skin cancer. It is usually recommended to individuals with extensive sun damage, history of multiple skin cancers, or rudimentary forms of cancer (i.e., solar keratosis). [37] It is often repeated every 2 to 3 years to further decrease the risk of skin cancer.[ citation needed ]

Treatment

The following methods are employed in the treatment of basal-cell carcinoma (BCC):

Standard surgical excision

Basal cell carcinoma, right cheek, marked for biopsy Basal Cell Carcinoma, Right cheek.jpg
Basal cell carcinoma, right cheek, marked for biopsy

Surgery to remove the basal-cell carcinoma affected area and the surrounding skin is thought to be the most effective treatment. [38] A disadvantage with standard surgical excision is a reported higher recurrence rate of basal-cell cancers of the face, [39] especially around the eyelids, [40] nose, and facial structures. [41] There is no clear approach, nor a clear research comparing the effectiveness of Mohs micrographic surgery versus surgical excision for BCC of the eye. [42]

For basal cell carcinoma excisions on the lower lip the wound can be covered with a keystone flap. A keystone flap is achieved by creating a flap below the defect and pulling it superiorly to cover the wound. This can be performed if there is enough skin laxity to cover the defect and adequate blood supply to the flap. [43]

Mohs surgery

For many new (primary) and all recurrent forms of basal cell carcinoma after previous surgery, especially on the head, neck, hands, feet, genitalia and anterior legs (shins), Mohs surgery should be considered. [44] [45]

Mohs surgery (or Mohs micrographic surgery) is an outpatient procedure, developed by Frederic E. Mohs in the 1930s, [22] in which the tumor is surgically excised and then immediately examined under a microscope. It is a form of pathology processing called CCPDMA, which means that the entire surgical margin (both edges and deep) is examined. During the surgery, after each removal of tissue and while the patient waits, the tissue is examined for cancer cells. That examination dictates the decision for additional tissue removal. Mohs surgery is also used for squamous-cell carcinoma, melanoma, atypical fibroxanthoma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, microcystic adnexal carcinoma, and multiple other skin cancers; [45] [46] usually with cure rates higher than for other surgical and non-surgical treatments. [46]

An essential aspect of Mohs surgery is that the Mohs surgeon performs the surgery and personally reviews the Mohs pathology slides. [45] Most standard excisions done in an office setting are sent to an outside laboratory for standard bread loafing method of processing. [47] With this method, it is likely that less than 5% of the surgical margin is examined, as each slice of tissue is only 6 micrometres thick, about 3 to 4 serial slices are obtained per section, and only about 3 to 4 sections are obtained per specimen. [48]

Cryosurgery

Cryosurgery is an old modality for the treatment of many skin cancers. When accurately utilized with a temperature probe and cryotherapy instruments, it can result in very good cure rate. Disadvantages include lack of margin control, tissue necrosis, over or under treatment of the tumor, and long recovery time. Overall, there are sufficient data to consider cryosurgery as a reasonable treatment for BCC. There are no good studies, however, comparing cryosurgery with other modalities, particularly with Mohs surgery, excision, or electrodesiccation and curettage so that no conclusion can be made whether cryosurgery is as efficacious as other methods. Also, there is no evidence on whether curetting the lesions before cryosurgery affects the efficacy of treatment. [49] Several textbooks are published on the therapy, and a few physicians still apply the treatment to selected patients. [50]

Electrodesiccation and curettage

Electrodesiccation and curettage (EDC, also known as curettage and cautery, simply curettage) [51] is accomplished by using a round knife, or curette, to scrape away the soft cancer. The skin is then burned with an electric current. This further softens the skin, allowing for the knife to cut more deeply with the next layer of curettage. The cycle is repeated, with a safety margin of curettage of normal skin around the visible tumor. This cycle is repeated 3 to 5 times, and the free skin margin treated is usually 4 to 6 mm. Cure rate is very much user-dependent and depends also on the size and type of tumor. Infiltrative or morpheaform BCCs can be difficult to eradicate with EDC. Generally, this method is used on cosmetically unimportant areas like the trunk (torso). Some physicians believe that it is acceptable to utilize EDC on the face of elderly patients over the age of 70. However, with increasing life expectancy, such an objective criterion cannot be supported. The cure rate can vary, depending on the aggressiveness of the EDC and the free margin treated. Some advocate curettage alone without electrodesiccation, and with the same cure rate. [52]

Chemotherapy

Some superficial cancers respond to local therapy with 5-fluorouracil, a chemotherapy agent. One can expect a great deal of inflammation with this treatment. [53] Chemotherapy often follows Mohs surgery to eliminate the residual superficial basal-cell carcinoma after the invasive portion is removed. 5-fluorouracil has received FDA approval.

Removing the residual superficial tumor with surgery alone can result in large and difficult to repair surgical defects. One often waits a month or more after surgery before starting the immunotherapy or chemotherapy to make sure the surgical wound has adequately healed. Some people[ who? ] advocate the use of curettage (see EDC below) first, followed by chemotherapy. These experimental procedures are not standard care. [51]

Vismodegib and sonidegib are drugs approved for specially treating BCC, but are expensive and cannot be used in pregnant women.

Itraconazole, traditionally an anti-fungal medication, has also garnered recent attention for its potential use in the treatment of BCC, especially those that cannot be removed surgically. Possessing anti-Hedgehog pathway activity, there is clinical evidence that itraconazole has some efficacy either alone or when combined with vismodegib/sonidegib for primary and recurrent BCC. There is one case report of efficacy in metastatic BCC. [54]

Immunotherapy

This technique uses the body's immune system to kill cancer cells. Improvement of the immune system works its way out up to the cancerous cells and treat the skin cancer.

Topical treatment with 5% Imiquimod cream (IMQ), with five applications per week for six weeks has a reported 70–90% success rate at reducing, even removing, the BCC [basal-cell carcinoma]. Imiquimod has received FDA approval, and topical IMQ is approved by the European Medicines Agency for treatment of small superficial basal-cell carcinoma. [51] Off label use of imiquimod on invasive basal-cell carcinoma has been reported. Imiquimod may be used prior to surgery in order to reduce the size of the carcinoma.

Some advocate the use of imiquimod prior to Mohs surgery to remove the superficial component of the cancer. [55]

Research suggests that treatment using Euphorbia peplus , a common garden weed, may be effective. [56] Australian biopharmaceutical company Peplin [57] is developing this as topical treatment for BCC.

Radiation

Radiation therapy can be delivered either as external beam radiotherapy or as brachytherapy (mostly internal radiotherapy). Although radiotherapy is generally used in older patients who are not candidates for surgery, it is also used in cases where surgical excision will be disfiguring or difficult to reconstruct (especially on the tip of the nose, and the nostril rims). Radiation treatment with external radiation often takes as few as 5 visits to as many as 25 visits. Usually, the more visits scheduled for therapy, the less complication or damage is done to the normal tissue supporting the tumor. Radiotherapy can also be useful if surgical excision has been done incompletely or if the pathology report following surgery suggests a high risk of recurrence, for example if nerve involvement has been demonstrated. Cure rate can be as high as 95% for small tumor, or as low as 80% for large tumors. A variation of an external brachytherapy is the epidermal radioisotope therapy (e.g. with 188Re in form of the Rhenium-SCT). It is used in accordance to the general indications for brachytherapy and especially complex localisations or structures (e.g. earlobe) as well as the genitals. [58]

Usually, recurrent tumors after radiation are treated with surgery, and not with radiation. Further radiation treatment will further damage normal tissue, and the tumor might be resistant to further radiation. Radiation therapy may be contraindicated for treatment of nevoid basal-cell carcinoma syndrome. A 2008 study reported that radiation therapy is appropriate for primary BCCs and recurrent BCCs, but not for BCCs that have recurred following previous radiation treatment. [51]

Photodynamic therapy

Photodynamic therapy (PDT) is a new modality for treatment of basal-cell carcinoma, which is administered by application of photosensitizers to the target area. When these molecules are activated by light, they become toxic, therefore destroying the target cells. Methyl aminolevulinate is approved by EU as a photosensitizer since 2001. This therapy is also used in other skin cancer types. [59] A 2008 study reported that PDT was a good treatment option for primary superficial BCCs and reasonable for primary low-risk nodular BCCs, but was a "relatively poor" option for high-risk lesions. [51]

Prognosis

Prognosis is excellent if the appropriate method of treatment is used in early primary basal-cell cancers. Recurrent cancers are much harder to cure, with a higher recurrence rate with any methods of treatment. Although basal-cell carcinoma rarely metastasizes, it grows locally with invasion and destruction of local tissues. The cancer can impinge on vital structures like nerves and result in loss of sensation or loss of function or rarely death. The vast majority of cases can be successfully treated before serious complications occur. The recurrence rate for the above treatment options ranges from 50 percent to 1 percent or less.

Epidemiology

Basal-cell cancer is a very common skin cancer. It is much more common in fair-skinned individuals with a family history of basal-cell cancer and increases in incidence closer to the equator or at higher altitude. It is very common among elderly people over the age of 80. [60] There are approximately 800,000 [61] new cases yearly in the United States alone. Up to 30% of white people develop basal-cell carcinomas in their lifetime. [62] In Canada, the most common skin cancer is basal-cell carcinoma (as much as one third of all cancer diagnoses), affecting 1 in 7 individuals over a lifetime. [63]

In the United States, approximately 3 out of 10 Caucasian people develop a basal-cell carcinoma during their lifetime. [62] This tumor accounts for approximately 70% of non-melanoma skin cancers. In 80 percent of all cases, basal-cell carcinoma affects head or neck skin. [62]

Most sporadic BCC arises in small numbers on sun-exposed skin of people over age 50, although younger people may also be affected. The development of multiple basal-cell cancer at an early age could be indicative of nevoid basal-cell carcinoma syndrome, also known as Gorlin syndrome. [64]

Notes

  1. ↑ Desmoplastic tricoepithelioma is particularly similar to basal-cell carcinoma.

Related Research Articles

<span class="mw-page-title-main">Skin cancer</span> Medical condition involving uncontrolled growth of skin cells

Skin cancers are cancers that arise from the skin. They are due to the development of abnormal cells that have the ability to invade or spread to other parts of the body. Skin cancer is the most commonly diagnosed form of cancer in humans. There are three main types of skin cancers: basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. The first two, along with a number of less common skin cancers, are known as nonmelanoma skin cancer (NMSC). Basal-cell cancer grows slowly and can damage the tissue around it but is unlikely to spread to distant areas or result in death. It often appears as a painless raised area of skin that may be shiny with small blood vessels running over it or may present as a raised area with an ulcer. Squamous-cell skin cancer is more likely to spread. It usually presents as a hard lump with a scaly top but may also form an ulcer. Melanomas are the most aggressive. Signs include a mole that has changed in size, shape, color, has irregular edges, has more than one color, is itchy or bleeds.

Dermatology is the branch of medicine dealing with the skin. It is a speciality with both medical and surgical aspects. A dermatologist is a specialist medical doctor who manages diseases related to skin, hair, nails, and some cosmetic problems.

<span class="mw-page-title-main">Cutaneous squamous-cell carcinoma</span> Medical condition

Cutaneous squamous-cell carcinoma (cSCC), also known as squamous-cell carcinoma of the skin or squamous-cell skin cancer, is one of the three principal types of skin cancer, alongside basal-cell carcinoma and melanoma. cSCC typically presents as a hard lump with a scaly surface, though it may also present as an ulcer. Onset and development often occurs over several months. Compared to basal cell carcinoma, cSCC is more likely to spread to distant areas. When confined to the epidermis, the outermost layer of the skin, the pre-invasive or in situ form of cSCC is termed Bowen's disease.

<span class="mw-page-title-main">Melanoma</span> Cancer originating in melanocytes

Melanoma is the most dangerous type of skin cancer; it develops from the melanin-producing cells known as melanocytes. It typically occurs in the skin, but may rarely occur in the mouth, intestines, or eye. In women, melanomas most commonly occur on the legs; while in men, on the back. Melanoma is frequently referred to as malignant melanoma. However, the medical community stresses that there is no such thing as a 'benign melanoma' and recommends that the term 'malignant melanoma' should be avoided as redundant.

<span class="mw-page-title-main">Dermatofibrosarcoma protuberans</span> Medical condition

Dermatofibrosarcoma protuberans (DFSP) is a rare locally aggressive malignant cutaneous soft-tissue sarcoma. DFSP develops in the connective tissue cells in the middle layer of the skin (dermis). Estimates of the overall occurrence of DFSP in the United States are 0.8 to 4.5 cases per million persons per year. In the United States, DFSP accounts for between 1 and 6 percent of all soft-tissue sarcomas and 18 percent of all cutaneous soft-tissue sarcomas. In the Surveillance, Epidemiology and End Results (SEER) tumor registry from 1992 through 2004, DFSP was second only to Kaposi sarcoma.

<span class="mw-page-title-main">Actinic keratosis</span> Skin disorder

Actinic keratosis (AK), sometimes called solar keratosis or senile keratosis, is a pre-cancerous area of thick, scaly, or crusty skin. Actinic keratosis is a disorder of epidermal keratinocytes that is induced by ultraviolet (UV) light exposure. These growths are more common in fair-skinned people and those who are frequently in the sun. They are believed to form when skin gets damaged by UV radiation from the sun or indoor tanning beds, usually over the course of decades. Given their pre-cancerous nature, if left untreated, they may turn into a type of skin cancer called squamous cell carcinoma. Untreated lesions have up to a 20% risk of progression to squamous cell carcinoma, so treatment by a dermatologist is recommended.

<span class="mw-page-title-main">Benign tumor</span> Mass of cells which cannot spread throughout the body

A benign tumor is a mass of cells (tumor) that does not invade neighboring tissue or metastasize. Compared to malignant (cancerous) tumors, benign tumors generally have a slower growth rate. Benign tumors have relatively well differentiated cells. They are often surrounded by an outer surface or stay contained within the epithelium. Common examples of benign tumors include moles and uterine fibroids.

<span class="mw-page-title-main">Lumpectomy</span> Limited surgical removal of breast tissue

Lumpectomy is a surgical removal of a discrete portion or "lump" of breast tissue, usually in the treatment of a malignant tumor or breast cancer. It is considered a viable breast conservation therapy, as the amount of tissue removed is limited compared to a full-breast mastectomy, and thus may have physical and emotional advantages over more disfiguring treatment. Sometimes a lumpectomy may be used to either confirm or rule out that cancer has actually been detected. A lumpectomy is usually recommended to patients whose cancer has been detected early and who do not have enlarged tumors. Although a lumpectomy is used to allow for most of the breast to remain intact, the procedure may result in adverse affects that can include sensitivity and result in scar tissue, pain, and possible disfiguration of the breast if the lump taken out is significant. According to National Comprehensive Cancer Network guidelines, lumpectomy may be performed for ductal carcinoma in situ (DCIS), invasive ductal carcinoma, or other conditions.

<span class="mw-page-title-main">Merkel-cell carcinoma</span> Rare and highly aggressive skin cancer

Merkel-cell carcinoma (MCC) is a rare and aggressive skin cancer occurring in about three people per million members of the population. It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, and trabecular carcinoma of the skin. Factors involved in the development of MCC include the Merkel cell polyomavirus, a weakened immune system, and exposure to ultraviolet radiation. Merkel-cell carcinoma usually arises on the head, neck, and extremities, as well as in the perianal region and on the eyelid. It is more common in people over sixty years old, Caucasian people, and males. MCC is less common in children.

<span class="mw-page-title-main">Lentigo maligna</span> Medical condition

Lentigo maligna is where melanocyte cells have become malignant and grow continuously along the stratum basale of the skin, but have not invaded below the epidermis. Lentigo maligna is not the same as lentigo maligna melanoma, as detailed below. It typically progresses very slowly and can remain in a non-invasive form for years.

<span class="mw-page-title-main">Keratoacanthoma</span> Medical condition

Keratoacanthoma (KA) is a common low-grade rapidly-growing skin tumour that is believed to originate from the hair follicle and can resemble squamous cell carcinoma.

<span class="mw-page-title-main">Mohs surgery</span> Surgery used to treat skin cancers

Mohs surgery, developed in 1938 by a general surgeon, Frederic E. Mohs, is microscopically controlled surgery used to treat both common and rare types of skin cancer. During the surgery, after each removal of tissue and while the patient waits, the tissue is examined for cancer cells. That examination dictates the decision for additional tissue removal. Mohs surgery is the gold standard method for obtaining complete margin control during removal of a skin cancer using frozen section histology. CCPDMA or Mohs surgery allows for the removal of a skin cancer with very narrow surgical margin and a high cure rate.

<span class="mw-page-title-main">Cryoablation</span> Process using extreme cold to destroy tissue

Cryoablation is a process that uses extreme cold to destroy tissue. Cryoablation is performed using hollow needles (cryoprobes) through which cooled, thermally conductive, fluids are circulated. Cryoprobes are positioned adjacent to the target in such a way that the freezing process will destroy the diseased tissue. Once the probes are in place, the attached cryogenic freezing unit removes heat from ("cools") the tip of the probe and by extension from the surrounding tissues.

<span class="mw-page-title-main">Skin biopsy</span> Removal of skin cells for medical examination

Skin biopsy is a biopsy technique in which a skin lesion is removed to be sent to a pathologist to render a microscopic diagnosis. It is usually done under local anesthetic in a physician's office, and results are often available in 4 to 10 days. It is commonly performed by dermatologists. Skin biopsies are also done by family physicians, internists, surgeons, and other specialties. However, performed incorrectly, and without appropriate clinical information, a pathologist's interpretation of a skin biopsy can be severely limited, and therefore doctors and patients may forgo traditional biopsy techniques and instead choose Mohs surgery.

<span class="mw-page-title-main">Sebaceous carcinoma</span> Medical condition

Sebaceous carcinoma, also known as sebaceous gland carcinoma (SGc), sebaceous cell carcinoma, and meibomian gland carcinoma is an uncommon malignant cutaneous tumor. Most are typically about 1.4 cm at presentation. SGc originates from sebaceous glands in the skin and, therefore, may originate anywhere in the body where these glands are found. SGc can be divided into 2 types: periocular and extraocular. The periocular region is rich in sebaceous glands making it a common site of origin. The cause of these lesions in the vast majority of cases is unknown. Occasional cases may be associated with Muir-Torre syndrome. SGc accounts for approximately 0.7% of all skin cancers, and the incidence of SGc is highest in Caucasian, Asian, and Indian populations. Due to the rarity of this tumor and variability in clinical and histological presentation, SGc is often misdiagnosed as an inflammatory condition or a more common neoplasm. SGc is commonly treated with wide local excision or Mohs micrographic surgery, and the relative survival rates at 5 and 10 years are 92.72 and 86.98%, respectively.

<span class="mw-page-title-main">Spiradenoma</span> Medical condition

Spiradenomas (SA) are rare, benign cutaneous adnexal tumors that may progress to become their malignant counterparts, i.e. spiradenocarcinomas (SAC). Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. SA and SAC tumors were regarded as eccrine gland tumors and termed eccrine spiradenomas and eccrine spiradenocarcinomas, respectively. However, more recent studies have found them to be hair follicle tumors and commonly term them spiradenomas and spiradenocarcinomas, respectively. Further confusing the situation, SA-like and SAC-like tumors are also 1) manifestations of the inherited disorder, CYLD cutaneous syndrome (CCS), and 2) have repeatedly been confused with an entirely different tumor, adenoid cystic carcinomas of the salivary gland. Here, SA and SAC are strictly defined as sporadic hair follicle tumors that do not include the hereditary CCS spiradenomas and heridtary spiradenocarcinoms of CCS or the adenoid cystic carcinomas.

<span class="mw-page-title-main">Microcystic adnexal carcinoma</span> Medical condition

Microcystic adnexal carcinoma (MAC) is a rare sweat gland cancer, which often appears as a yellow spot or bump in the skin. It usually occurs in the neck or head, although cases have been documented in other areas of the body. Most diagnosis occur past the age of 50. Although considered an invasive cancer, metastasis rarely occurs. If the tumor spreads, it can grow and invade fat, muscles, and other types of tissue. Main treatments are wide local excision or Mohs micrographic surgery, which ensures that most, if not all, cancer cells are removed surgically.

<span class="mw-page-title-main">Eccrine carcinoma</span> Medical condition

Eccrine carcinoma is a rare skin condition characterized by a plaque or nodule on the scalp, trunk, or extremities. It originates from the eccrine sweat glands of the skin, accounting for less than 0.01% of diagnosed cutaneous malignancies. Eccrine carcinoma tumors are locally aggressive, with a high rate of recurrence. Lack of reliable immunohistochemical markers and similarity to other common tumors has made identification of eccrine carcinoma difficult.

Electrodesiccation and curettage is a medical procedure commonly performed by dermatologists, surgeons and general practitioners for the treatment of basal cell cancers and squamous cell cancers of the skin. It provides desiccation, coagulation/cauterization, and curettage to remove lesions from the skin.

CYLD cutaneous syndrome (CCS) is the recently designated term for three rare inherited cutaneous adnexal tumor syndromes: multiple familial trichoepithelioma (MFT1), Brooke–Spiegler syndrome (BSS), and familial cylindromatosis (FC). Cutaneous adnexal tumors are a large group of skin tumors that consist of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. CCS tumors are hair follicle tumors.

References

  1. 1 2 3 "Skin Cancer Treatment (PDQ®)". NCI. 2013-10-25. Archived from the original on 5 July 2014. Retrieved 30 June 2014.
  2. 1 2 3 4 5 6 7 8 9 10 Gandhi SA, Kampp J (November 2015). "Skin Cancer Epidemiology, Detection, and Management". The Medical Clinics of North America. 99 (6): 1323–35. doi:10.1016/j.mcna.2015.06.002. PMID   26476255.
  3. 1 2 "Skin Cancer Treatment". National Cancer Institute. 21 June 2017. Archived from the original on 4 July 2017. Retrieved 2 July 2017.
  4. ↑ Krutmann J, Humbert P (2010). Nutrition for Healthy Skin: Strategies for Clinical and Cosmetic Practice. Springer. p. 31. ISBN   978-3-642-12264-4. Archived from the original on 2017-09-10.
  5. 1 2 World Cancer Report 2014. World Health Organization. 2014. Chapter 5.14. ISBN   978-92-832-0429-9.
  6. ↑ GBD 2015 Mortality and Causes of Death Collaborators (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC   5388903 . PMID   27733281.
  7. ↑ "Basal Cell Carcinoma". dermnetnz.org. Retrieved 12 November 2023.
  8. ↑ "Basal Cell Carcinoma (Rodent Ulcer or BCC)". Newcastle Hospitals NHS Foundation Trust. 31 October 2022. Retrieved 12 November 2023.
  9. 1 2 Cakir BÖ, Adamson P, Cingi C (November 2012). "Epidemiology and economic burden of nonmelanoma skin cancer". Facial Plastic Surgery Clinics of North America. 20 (4): 419–22. doi:10.1016/j.fsc.2012.07.004. PMID   23084294.
  10. ↑ Gallagher RP, Lee TK, Bajdik CD, Borugian M (2010). "Ultraviolet radiation". Chronic Diseases in Canada. 29 (Suppl 1): 51–68. doi:10.24095/hpcdp.29.S1.04. PMID   21199599. The major source of ultraviolet radiation is solar radiation or sunlight. However, exposure to artificial sources particularly through tanning salons is becoming more important in terms of human health effects, as use of these facilities by young people, [ sic ] has increased.
  11. ↑ Jou PC, Feldman RJ, Tomecki KJ (June 2012). "UV protection and sunscreens: what to tell patients". Cleveland Clinic Journal of Medicine. 79 (6): 427–36. doi: 10.3949/ccjm.79a.11110 . PMID   22660875. S2CID   44457153.
  12. 1 2 "Skin Cancer Treatment". National Cancer Institute. 21 June 2017. Archived from the original on 4 July 2017. Retrieved 2 July 2017.
  13. ↑ Dubas LE, Ingraffea A (February 2013). "Nonmelanoma skin cancer". Facial Plastic Surgery Clinics of North America. 21 (1): 43–53. doi:10.1016/j.fsc.2012.10.003. PMID   23369588.
  14. ↑ "Basal Cell Carcinoma Warning Signs and Images". The Skin Cancer Foundation. Retrieved 2023-03-02.
  15. 1 2 "Genetics of Skin Cancer". National Cancer Institute. 2009-07-29. Retrieved 2019-05-06.
  16. 1 2 "Basal Cell Carcinoma - Skin Disorders". MSD Manual Consumer Version.
  17. ↑ Boettler MA, Shahwan KT, Abidi NY, Carr DR (2022). "Trichoblastic carcinoma: a comprehensive review of the literature". Arch Dermatol Res. 314 (5): 399–403. doi:10.1007/s00403-021-02241-y. PMID   33993349. S2CID   234598207.
  18. ↑ Laffay L, Depaepe L, d'Hombres A, Balme B, Thomas L, De Bari B (2012). "Histological features and treatment approach of trichoblastic carcinomas: from a case report to a review of the literature". Tumori. 98 (2): 46e–49e. doi:10.1700/1088.11948 (inactive 2024-03-13). PMID   22678003.{{cite journal}}: CS1 maint: DOI inactive as of March 2024 (link)
  19. ↑ Cribier B (2018). "From basal cell carcinoma to trichoblastic tumors: a diagnostic challenge". Ann Dermatol Venereol (in French). 145 (Suppl 5): VS3–VS11. doi:10.1016/S0151-9638(18)31254-7. PMID   30477681. S2CID   81618758.
  20. ↑ Ackerman AB, Kerl H, Sánchez J, Guo Y (2000). "Basal-cell carcinoma: integration unifying concept". A clinical atlas of 101 common skin diseases : with histopathologic correlation. New York: Ardor Scribendi. ISBN   978-1-893357-10-5.
  21. ↑ Fusco N, Lopez G, Gianelli U (September 2015). "Basal-Cell Carcinoma and Seborrheic Keratosis: When Opposites Attract". International Journal of Surgical Pathology. 23 (6): 464. doi:10.1177/1066896915593802. PMID   26135529. S2CID   206650583.
  22. 1 2 Epstein EH, Shepard JA, Flotte TJ (January 2008). "Case records of the Massachusetts General Hospital. Case 3-2008. An 80-year-old woman with cutaneous basal-cell carcinomas and cysts of the jaws". The New England Journal of Medicine. 358 (4): 393–401. doi:10.1056/NEJMcpc0707893. PMID   18216361.
  23. ↑ "What Is Basal Cell Cancer". SkinCancerGuide. Archived from the original on 2009-03-01. Retrieved 2009-02-18.
  24. ↑ Ferrante di Ruffano L, Dinnes J, Chuchu N, Bayliss SE, Takwoingi Y, Davenport C, et al. (December 2018). "Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults". The Cochrane Database of Systematic Reviews. 2018 (12): CD013187. doi:10.1002/14651858.cd013187. PMC   6517175 . PMID   30521689.
  25. ↑ Robert S Bader. "Which histologic findings are characteristic of basal cell carcinoma (BCC)?". Medscape. Updated: Feb 21, 2019
  26. 1 2 Sunjaya AP, Sunjaya AF, Tan ST (2017). "The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma". Journal of Skin Cancer. 2017: 1–10. doi: 10.1155/2017/2692604 . PMC   5804366 . PMID   29464122.
  27. 1 2 3 4 5 6 Initially copied from: Paolino G, Donati M, Didona D, Mercuri S, Cantisani C (2017). "Histology of Non-Melanoma Skin Cancers: An Update". Biomedicines. 5 (4): 71. doi: 10.3390/biomedicines5040071 . PMC   5744095 . PMID   29261131.
  28. 1 2 3 4 5 6 7 8 Freedberg, et al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). McGraw-Hill. ISBN   0-07-138076-0.
  29. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 James WD, Berger TG, et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN   978-0-7216-2921-6.
  30. ↑ Robert S Bader. "Which histologic findings are characteristic of basal cell carcinoma (BCC)?". Medscape . Updated: Feb 21, 2019
  31. ↑ East E, Fullen DR, Arps D, Patel RM, Palanisamy N, Carskadon S, et al. (2016). "Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration". The American Journal of Dermatopathology. 38 (10): 744–50. doi:10.1097/DAD.0000000000000541. PMID   27043336. S2CID   44948030.
  32. ↑ Haddock ES, Cohen PR (September 2016). "Fibroepithelioma of Pinkus Revisited". Dermatology and Therapy. 6 (3): 347–62. doi:10.1007/s13555-016-0123-8. PMC   4972729 . PMID   27329375.
  33. ↑ From the "Glas classification" or "Sabbatsberg classification": Krynitz B, Olsson H, Lundh Rozell B, Lindelöf B, Edgren G, Smedby K (2016). "Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study". British Journal of Dermatology. 174 (1): 95–103. doi:10.1111/bjd.14153. PMID   26333521. S2CID   43844922.
  34. ↑ Yonan Y, Maly C, DiCaudo D, Mangold A, Pittelkow M, Swanson D (2019). "Dermoscopic Description of Fibroepithelioma of Pinkus with Negative Network". Dermatology Practical & Conceptual. 9 (3): 246–7. doi:10.5826/dpc.0903a23. PMC   6659602 . PMID   31384511. Creative Commons Attribution License
  35. ↑ Inskip M, Magee J (2015). "Microcystic adnexal carcinoma of the cheek – a case report with dermatoscopy and dermatopathology". Dermatology Practical & Conceptual. 5 (1): 43–46. doi:10.5826/dpc.0501a07. PMC   4325690 . PMID   25692080.
  36. ↑ Sánchez G, Nova J, Rodriguez-Hernandez AE, Medina RD, Solorzano-Restrepo C, Gonzalez J, et al. (July 2016). "Sun protection for preventing basal-cell and squamous cell skin cancers". The Cochrane Database of Systematic Reviews. 7 (9): CD011161. doi:10.1002/14651858.CD011161.pub2. PMC   6457780 . PMID   27455163.
  37. ↑ Weinstock MA, Thwin SS, Siegel JA, Marcolivio K, Means AD, Leader NF, et al. (February 2018). "Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial". JAMA Dermatology. 154 (2): 167–74. doi:10.1001/jamadermatol.2017.3631. PMC   5839275 . PMID   29299592.
  38. ↑ Thomson J, Hogan S, Leonardi-Bee J, Williams HC, Bath-Hextall FJ (November 17, 2020). "Interventions for basal cell carcinoma of the skin". The Cochrane Database of Systematic Reviews. 11 (12): CD003412. doi:10.1002/14651858.CD003412.pub3. PMC   8164471 . PMID   33202063.
  39. ↑ Basal Cell and Squamous Cell Skin Cancers (PDF). NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. 2009. p. 38. Archived from the original (PDF) on 2009-02-27.
  40. ↑ Sigurdsson H, Agnarsson BA (August 1998). "Basal cell carcinoma of the eyelid. Risk of recurrence according to adequacy of surgical margins". Acta Ophthalmologica Scandinavica. 76 (4): 477–80. doi: 10.1034/j.1600-0420.1998.760416.x . PMID   9716337.
  41. ↑ Farhi D, Dupin N, Palangié A, Carlotti A, Avril MF (October 2007). "Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases". Dermatologic Surgery. 33 (10): 1207–14. doi:10.1111/j.1524-4725.2007.33255.x. PMID   17903153. S2CID   19202086.
  42. ↑ Narayanan K, Hadid OH, Barnes EA (December 2014). "Mohs micrographic surgery versus surgical excision for periocular basal-cell carcinoma". The Cochrane Database of Systematic Reviews. 2014 (12): CD007041. doi:10.1002/14651858.CD007041.pub4. PMC   7390281 . PMID   25503105.
  43. ↑ Hallock G (2020). "Basal Cell Carcinoma Excision from Lower Lip with Keystone Flap Reconstruction". J Med Ins. 2023 (10). doi:10.24296/jomi/290.6. 290.6.
  44. ↑ Bichakjian CK, Olencki T, Olencki SZ (2016). "Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology". J Natl Compr Canc Netw. 14 (May): 574–597. doi: 10.6004/jnccn.2016.0065 . PMID   27160235.
  45. 1 2 3 Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM (2012). "AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery". J Am Acad Dermatol. 67 (4): 531–550. doi:10.1016/j.jaad.2012.06.009. PMID   22959232.
  46. 1 2 Mansouri B, Bicknell LM, Hill D, Walker GD, Fiala K, Housewright C (2017-08-01). "Mohs Micrographic Surgery for the Management of Cutaneous Malignancies". Facial Plastic Surgery Clinics of North America. Facial Reconstruction Post-Mohs Surgery. 25 (3): 291–301. doi:10.1016/j.fsc.2017.03.002. PMID   28676157.
  47. ↑ Lane JE, Kent DE (2005). "Surgical margins in the treatment of nonmelanoma skin cancer and mohs micrographic surgery". Current Surgery. 62 (5): 518–26. doi:10.1016/j.cursur.2005.01.003. PMID   16125611.
  48. ↑ Maloney ME, Torres A, Hoffman TJ (1999). Surgical Dermatopathology. Blackwell. p. 113. ISBN   978-0-86542-299-5.
  49. ↑ Kokoszka A, Scheinfeld N (June 2003). "Evidence-based review of the use of cryosurgery in treatment of basal-cell carcinoma". Dermatologic Surgery. 29 (6): 566–71. doi:10.1046/j.1524-4725.2003.291511.x. PMID   12786697.
  50. ↑ "Understanding Actinic Keratosis – Treatment". Web MD. Archived from the original on 2007-08-11. Retrieved 2008-12-05.
  51. 1 2 3 4 5 Telfer NR, Colver GB, Morton CA (July 2008). "Guidelines for the management of basal-cell carcinoma". The British Journal of Dermatology. 159 (1): 35–48. doi:10.1111/j.1365-2133.2008.08666.x. PMID   18593385. S2CID   12365983.
  52. ↑ Barlow JO, Zalla MJ, Kyle A, DiCaudo DJ, Lim KK, Yiannias JA (June 2006). "Treatment of basal cell carcinoma with curettage alone". Journal of the American Academy of Dermatology. 54 (6): 1039–45. doi:10.1016/j.jaad.2006.01.041. PMID   16713459.
  53. ↑ Archived 2009-05-20 at the Wayback Machine
  54. ↑ Ip KH, McKerrow K (2021). "Itraconazole in the treatment of basal cell carcinoma: A case-based review of the literature". Australasian Journal of Dermatology. 62 (3): 394–397. doi:10.1111/ajd.13655. PMID   34160824. S2CID   235608763.
  55. ↑ Butler DF, Parekh PK, Lenis A (January 2009). "Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal-cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study". Dermatologic Surgery. 35 (1): 24–29. doi: 10.1111/j.1524-4725.2008.34378.x . PMID   19018814. S2CID   45091789.
  56. ↑ "Peplin's skin cancer gel trial a success". The Age. Melbourne. 1 May 2006. Archived from the original on 16 June 2006.
  57. ↑ Peplin Archived June 14, 2008, at the Wayback Machine
  58. ↑ Castellucci P, Savoia F, Farina A, Lima GM, Patrizi A, Baraldi C, et al. (2020-11-02). "High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results". European Journal of Nuclear Medicine and Molecular Imaging. 48 (5): 1511–21. doi:10.1007/s00259-020-05088-z. PMC   8113182 . PMID   33140131.
  59. ↑ Peng Q, Juzeniene A, Chen J, Svaasand LO, Warloe T, Giercksky K, et al. (2008). "Lasers in medicine". Reports on Progress in Physics. 71 (5): 056701. Bibcode:2008RPPh...71e6701P. doi:10.1088/0034-4885/71/5/056701. S2CID   119815301.
  60. ↑ Lubeek SF, van Vugt LJ, Aben KK, van de Kerkhof PC, Gerritsen MP (2017). "The epidemiology and clinicopathological features of basal cell carcinoma in patients 80 years and older: a systematic review". JAMA Dermatol. 153 (1): 71–78. doi:10.1001/jamadermatol.2016.3628. PMID   27732698. S2CID   8964342.
  61. ↑ Skin Cancer Foundation: Basal-Cell Carcinoma Archived 2006-06-19 at the Wayback Machine
  62. 1 2 3 Wong CS, Strange RC, Lear JT (October 2003). "Basal cell carcinoma". BMJ. 327 (7418): 794–98. doi:10.1136/bmj.327.7418.794. PMC   214105 . PMID   14525881.
  63. ↑ "Epidemiology of Skin Cancer". BC Cancer Agency. Archived from the original on 2011-05-14. Retrieved 2011-06-25.
  64. ↑ Gorlin RJ (2008). "Nevoid Basal Cell Carcinoma (Gorlin) Syndrome". Neurocutaneous Disorders Phakomatoses and Hamartoneoplastic Syndromes. pp. 669–94. doi:10.1007/978-3-211-69500-5_45. ISBN   978-3-211-21396-4.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.